Floatz logo

Eszopiclone

Parkinson Disease

University of Medicine and Dentistry of New JerseySmall moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
73/ 100

Competitive context

241 Active assets in the Parkinson Disease cohort.

Asset / SponsorPhaseRating
Safinamide
Zambon SpA
Phase 4A
Cvt-301
Acorda Therapeutics
Phase 3A
Istradefylline
Georgetown University
Phase 4BBB
Rasagiline
Guangzhou Henovcom Bioscience Co. Ltd.
Phase 4BBB
Pardoprunox
Abbott Products
Phase 3BBB

View all 50 →

Same molecule, other indications

Eszopiclone is also rated in:

insomniaDormant
A
Indicative · Phase 4
82 / 100
View asset →
major depressive disorderDormant
BB
Indicative · Phase 4
66 / 100
View asset →
migraine disorderDormant
B
Indicative · Phase 4
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →